arrow
E

Edward Rosfjord

Pfizer
H指数:23
被引数:2,757

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate

EGFR/c-met靶向双特异性抗体药物偶联物AZD9592的靶向表达与体内抗肿瘤疗效的关系评价

2023-04-047
PRE
Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and Toxicity
2022-12-023
OA
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

纤连蛋白抗体-药物偶联物的抗外域B剪接变体与检查点阻断相结合可消除肿瘤,并提高疗效

2022-07-069
OAAI
Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy
2021-06-188
OAAI
Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors
MABS
IF7.3
2021-01-1810
OAAI
PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2020-10-0240
OAAI
A novel GUCY2C-CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors
2020-08-150
PRE
A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers
2020-05-0135
OA
Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity

胱氨酸-谷氨酸反向转运体xCT缺陷抑制肿瘤生长,同时保持抗肿瘤免疫力

2019-04-24126
OAAI
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
2017-01-11138
PREAI
A novel PTK7-targeted antibody-drug conjugate eliminates tumor-initiating cells and induces sustained tumor regressions
2016-07-150
PRE